ArticleThe Lancet regional health. Europe2025
Burden of bacterial antimicrobial resistance among hospitalised patients in Spain: findings from three nationwide prospective studies.
Article in The Lancet regional health. Europe, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Appropriateness of surgical antibiotic prophylaxis in Spanish hospitals: a national multicentre cross-sectional study.The Lancet regional health. Europe · 2026Article
- Cefepime susceptibility testing in AmpC-hyperproducing Enterobacter cloacae complex: limitations of routine methods and a pragmatic diagnostic approach.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- ASP-COMPLEX: redefining antimicrobial stewardship to improve outcomes in high-risk patients with severe infections.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026Review
- An ATP-Mediated Antibiotic β-Peptide Nanofiber That Kills Multidrug-Resistant Bacteria via a Multistage Mechanism.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Impact of Susceptibility Testing Methodology on the Positioning of Cefiderocol and Aztreonam-Avibactam Against Metallo-β-Lactamase-Producing Gram-Negative Bacteria.Antibiotics (Basel, Switzerland) · 2026Article
- Mortality risk of ESBL producers in Escherichia coli bacteraemia: a comprehensive analysis using the PROBAC cohort.The Journal of antimicrobial chemotherapy · 2026Article
- The new Flemings now sing: a methodological evaluation of gamification and citizen science strategies to raise awareness on antimicrobial resistance.Immunology and cell biology · 2026Article
- Cost-Effectiveness Analysis of Aztreonam-Avibactam Compared with Colistin Plus Meropenem in Treating Metallo-Beta-Lactamase-Producing Enterobacterales Infections in Spain.Infectious diseases and therapy · 2026Article
- Pharmacokinetic/pharmacodynamic optimization of temocillin treatment against CTX-M-15-producingAntimicrobial agents and chemotherapy · 2025Article
- Classification and applicability of new beta-lactamase inhibitors.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2025Review
- Introduction to XIV updating course of antimicrobials and infectious diseases.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2025Review
- Burden of multi-drug-resistant organisms in a tertiary healthcare institute in North India: Implications for regional public health.World journal of experimental medicine · 2025Article
- Estimating the Value of Aztreonam-Avibactam in Treating Metallo-beta-Lactamase-Producing Enterobacterales Infections in Spain Using the STEDI AMR Value Framework.Infectious diseases and therapy · 2025Article
- Mortality related to multidrug-resistant microorganism infections: differentiating crude mortality from attributable mortality-author's reply.The Lancet regional health. Europe · 2025Article
- Mortality related to multidrug-resistant microorganism infections: differentiating crude mortality from attributable mortality.The Lancet regional health. Europe · 2025Article
- Multidrug-Resistant Infections and Metabolic Syndrome: An Overlooked Bidirectional Relationship.Biomedicines · 2025Review
- Phage Therapy for Hospital-Acquired Respiratory Bacterial Infections: A Review.Open respiratory archivesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Assessing the burden of antimicrobial resistance is essential to determine the magnitude of this problem and to set its priority. We aimed to estimate the burden of disease caused by multidrug-resistant microorganisms (MDRO) in hospitalised patients in Spain. Methods: Three prospective nationwide studies were conducted in 2018, 2019 and 2023. All patients with a new diagnosis of infection with any of 10 selected MDROs plus Findings: In total, 82, 133 and 130 centres participated in the study in 2018, 2019 and 2023, respectively, recording a total of 907, 1392 and 2351 MDRO infections, representing a weighted incidence density of 3.54 (95% CI 2.92-4.17), 5.01 (3.95-6.07), and 4.41 (3.55-5.27) cases/1000 stays, respectively. A total of 161, 198 and 352 patients died with an MDRO infection, representing a weighted incidence density of 0.46 (0.16-0.76), 0.43 (0.17-0.69), and 0.62 (0.52-0.72) deaths/1000 stays, respectively. Based on these data, a nationwide occurrence of 155,294 MDRO infections (95% CI 127,928-182,569) with 20,065 deaths (6938-32,958) was estimated for 2018, 210,451 MDRO infections (165,963-254,975) with 17,982 deaths (7071-28,700) for 2019, and 173,653 MDRO infections (139,814-207258) with 24,582 deaths (20,461-28,796) for 2023. Interpretation: The burden of disease caused by MDRO infections among hospitalised patients in Spain is very high and remains stable over the study period. National actions to combat bacterial resistance need to be intensified. Funding: The management costs of this study were funded by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). Researchers have participated voluntarily and none of the investigators received funding for conducting the study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.